<DOC>
	<DOCNO>NCT02981199</DOCNO>
	<brief_summary>Comparison efficacy safety microtransplantation autologous transplantation treatment ≥PR multiple myeloma patient , 2-year PFS OS also observe . To identify role microtransplantation treatment multiple myeloma .</brief_summary>
	<brief_title>Microtransplantation Versus Auto-SCT ≥PR Multiple Myeloma Patients</brief_title>
	<detailed_description>NDMM patient induction therapy 4 cycle PCD/PAD regimen , achieve ≥PR , eligible SCT , randomly divide two arm . One arm receive microtransplantation , accept auto-SCT . Comparison efficacy safety two arm , 2-year PFS OS also observe . Clear program relate hematopoietic recovery , remission rate , infection recurrence rate , survival rate formation micro inlay , minimal residual disease GVHD , etc . To identify role microtransplantation treatment multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Diagnosis MM compliance IMWG diagnostic criterion ( 2014 ) 2. induction therapy 4 cycle PCD/PAD regimen , achieve ≥PR 3 . KPS ≥60，ECOG≤2 4）Age 1865，eligible SCT 5）Heart function &lt; II level ( NYHA standard ) ejection fraction &gt; 50 % 1 . KPS＜60 2 . Allergy bortezomib , epirubicin , drug ingredient 3 . Severe hepatitis organ dysfunction : serious infection control ; cardiac ejection fraction &lt; 50 % , serum bilirubin &gt; 3mg/dl , severe abnormal result liver function test ( AST great 3 time upper limit ) , severe renal injury ; central nervous system disorder , uncontrolled mental illness 4 . With 2 bortezomib associate peripheral neuropathy neuralgia patient 5 . Patients active stage herpes zoster 6 . Women pregnancy lactation 7 . MM AL EM plasma cell tumor 8 . The patient refuse accept treatment signature 9 . Donor meet requirement : include HIV positive , active hepatitis B , bone marrow disease , donor refuse provide hematopoietic stem cell agree sign . 10 . Epirubicin / anthracyclines previously accumulate 240mg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>microtransplantation</keyword>
	<keyword>multiple myeloma</keyword>
</DOC>